What Jasper Therapeutics does

Jasper Therapeutics is a clinical-stage biotechnology company headquartered in Redwood City, California, that develops briquilimab, a proprietary anti-KIT (CD117) monoclonal antibody designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. Founded in 2019 and taken public via a 2021 SPAC merger with Notable on NASDAQ under ticker JSPR, the company's single-asset pipeline targets chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma — with discontinued programs in SCID and a paused asthma program following a July 2025 drug product contamination incident. Clinical data to date has shown meaningful efficacy signals, including 67% complete response at 12 weeks in the BEACON Phase 1b/2a study and significant eosinophil and lung function improvements in the ETESIAN Phase 1b asthma study, supporting a planned Phase 2b/3 CSU trial in 2H 2026.

The company's business model is that of a pre-revenue clinical-stage biotech: it generates no commercial revenue, has no product approvals, and funds operations exclusively through equity financings — most recently a $30M public offering in September 2025 at $2.43 per share, following a $50M raise in February 2024 and a $90M raise in January 2023. Cash reserves stood at $28.7M in Q4 2025 against a widened 2025 net loss of $75.8M. The go-to-market motion is entirely investor-relations-driven (conference participation, analyst coverage, IR webcasts), with no distribution or commercial infrastructure in place. Jasper is led by President and CEO Jeet Mahal (appointed January 2026) and Executive Chairperson Thomas Wiggans.

The company's near-term outlook is defined by financial distress and strategic uncertainty. In June 2026, the Board of Directors initiated a comprehensive strategic alternatives review evaluating potential sale of assets, licensing, collaborations, business combinations, or an orderly wind-down of operations, citing an imminent need for additional funding. With a single clinical-stage asset, a recent manufacturing quality failure, persistent operating losses, and limited runway, Jasper represents a high-risk, binary-outcome biotech investment where value depends on either successful strategic transaction execution or successful advancement of briquilimab into registrational trials.

Name

Jasper Therapeutics

Legal name

Jasper Therapeutics, Inc.

Website

https://jaspertherapeutics.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a proprietary anti-KIT monoclonal antibody that depletes mast cells to treat chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma. The pre-revenue company is exploring strategic alternatives following a 2025 manufacturing contamination incident.

Ownership category

akta.pro rank

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Marketing channels3 records

Core offering

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. The asset is being evaluated in clinical studies across chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and adult allergic asthma, with planned progression into a Phase 2b/3 trial in CSU in the second half of 2026. The company has no approved products and no commercial revenue.

Product overview

Jasper Therapeutics is a biotechnology company developing a single core product, briquilimab, which is a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases. The company's clinical pipeline focuses on evaluating briquilimab across multiple mast cell-driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. Jasper is conducting multiple clinical studies including the BEACON Phase 1b/2a study in CSU/CIndU and the ETESIAN Phase 1b study in asthma, with plans for a Phase 2b/3 trial in CSU in the second half of 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• Briquilimab

Quantifiable outcome

• 67% of patients achieved complete response at 12 weeks in BEACON Phase 1b/2a study
• +5 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Celldex Therapeutics: Celldex is developing barzolvolimab, an anti-KIT monoclonal antibody targeting mast cells, with clinical programs in CSU and other mast cell-driven diseases. It is the most directly comparable peer to Jasper given the shared anti-KIT mechanism and CSU focus.
• AB Science: AB Science is developing masitinib, a tyrosine kinase inhibitor that targets mast cell and c-Kit pathways, with clinical programs in mastocytosis and inflammatory diseases. Comparable as a mast cell pathway competitor in similar indications.

Emerging players

• Evommune: Evommune is a privately held biotech developing therapies for chronic inflammatory skin diseases including CSU and other mast cell-driven conditions. Relevant as an emerging competitor in overlapping dermatologic indications.
• Blueprint Medicines: Blueprint Medicines is developing Ayvakit (avapritinib), a KIT inhibitor approved for systemic mastocytosis and PDGFRA-driven disorders. Comparable as a developer of KIT-pathway targeted therapies with adjacent mast cell indications.
• Allakos: Allakos is developing antibody therapies (e.g., lirentelimab) targeting mast cell and eosinophil pathways for inflammatory diseases including CSU. Relevant as a clinical-stage developer of mast cell-directed biologics in overlapping indications.

Broad incumbents

• Novartis: Novartis co-markets omalizumab (Xolair) with Genentech, the current standard of care in CSU. It is the incumbent competitor that any new anti-KIT therapy must displace or complement in refractory CSU.
• Genentech (Roche): Genentech co-markets omalizumab (Xolair) for CSU and chronic inducible urticaria and has deep immunology franchise overlap with briquilimab's target indications. Sets the efficacy and pricing benchmark for any new CSU biologic.
• Sanofi: Sanofi markets Dupixent (dupilumab) for atopic dermatitis, asthma, and other type 2 inflammatory diseases, overlapping with Jasper's asthma and CSU development programs. A potential strategic acquirer or competitor in inflammatory disease markets.
• AstraZeneca: AstraZeneca markets severe asthma biologics Fasenra (benralizumab, anti-IL-5R) and Tezspire (anti-TSLP), overlapping with Jasper's allergic asthma program. Represents both a competing therapy and a potential strategic acquirer in respiratory inflammation.
• GSK: GSK markets Nucala (mepolizumab, anti-IL-5) for severe eosinophilic asthma and other inflammatory diseases, providing a comparator in the asthma space where briquilimab is being evaluated.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/JasperBio
• LinkedInlinkedin.com/company/jaspertherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds7 records

Investors32 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jasper Therapeutics